LAS VEGAS, July 11, 2025 (GLOBE NEWSWIRE) -- via IBN -- Glidelogic Corp. (USOTC: GDLG, "Glidelogic", "the Company") today announced the release of its first fully AI-generated novel titled The Thirteenth Proposal. The new novel, a political thriller of approximately 80,000 English words (with a 140,000-character Chinese edition), was written entirely by artificial intelligence systems. The Thirteenth Proposal, created by Glidelogic's proprietary Novagen AI based on outputs from Google Gemini 2.5 Pro and dev ...

Core Insights - Glidelogic Corp. has released its first fully AI-generated novel titled The Thirteenth Proposal, marking a significant milestone in AI-driven creativity [1][2][3] - The novel, a political thriller of approximately 80,000 words in English and 140,000 characters in Chinese, was created using Glidelogic's proprietary Novagen AI in collaboration with Google Gemini 2.5 Pro [1][2] - This project serves as an exploratory demonstration of AI's capabilities in creative storytelling, emphasizing that AI can complement human creativity rather than replace it [3][4] Company Overview - Glidelogic Corp. was founded in December 2020 and is headquartered in Las Vegas, Nevada, focusing on AI-based software, fintech solutions, and blockchain technology [5] - The company's mission is to leverage leading AI technology to enhance productivity for commercial clients [5]

PHILADELPHIA, July 11, 2025 (GLOBE NEWSWIRE) -- Enviri Corporation (NYSE: NVRI) today announced that it will issue its second quarter 2025 earnings results on Tuesday, August 5, 2025 prior to NYSE market open. The Company will also host its quarterly conference call and webcast that morning beginning at 9:00 a.m. ET. Those who wish to listen to the conference call webcast should visit the Investor Relations section of the Company’s website at www.enviri.com. The live call also can be accessed using the belo ...

机构：华创证券 研究员：刘一怡 事项： 根据Wind 资讯，Meta 以当前市价购入依视路近3%的股份，价值约30 亿欧元（约252 亿人民币）；而 且之后可能考虑追加投资，将持股比例提升至5%左右。 两种视角看Meta 入股依视路。1）产业链视角下：智能眼镜需要满足全天候佩戴需求，对镜片"超轻、 超薄、耐高温"的属性要求更高，且镜片作为智能眼镜唯一非标环节，Meta 直接入股依视路，类似歌尔 入股康耐特（第二大股东，占20%），均体现产业链对镜片企业的高度重视。2）商业模式视角下：镜 片行业本身毛利率较高，配合智能眼镜的定制镜片方案预计单位价值量更大，有望进一步打开镜片企业 价格空间。 近期产业链迎来密集催化，建议重视9 月Meta 新品。1）Oakley 官方于6 月20 日发布新品，新款眼镜基 于 Oakley HSTN 打造，专为骑行、跑步等运动爱好者设计；2）根据XR 研究院，小米AI 眼镜发布首周 销量约7 万台（含线上线下等所有渠道），预计小米AI 眼镜年销量30~40 万台；3）新品方面建议重视 后续9 月Meta 系列产品推出，如AR+AI 功能的Hypernova 系列和新一代AI 眼镜M ...

July 9, 2025 03:22 AM GMT China Healthcare | Asia Pacific M Update A Potential 200% US Tariff on Pharmaceuticals - How Feasible Is It? Key Takeaways Generic drugs: There is currently an acute shortage of sterile injectables in the US. A report from the US FDA earlier this year highlighted 102 generic medicines, 70% of which were injectables, that were under-supplied from 2019-2024. The biggest categories were anesthesia, endocrinology, gastroenterology, oncology, and cardiovascular injections (note). Generi ...

Core Points - V2X, Inc. will report its second quarter 2025 financial results on August 4, 2025, after market close [1] - A conference call with senior management will take place at 4:30 p.m. ET on the same day [1] - The company provides innovative solutions that integrate physical and digital environments, enhancing mission readiness and resource management [4] Financial Reporting - The second quarter 2025 financial results will be disclosed after market close on August 4, 2025 [1] - A live webcast and slide presentation will be available for investors [2] Conference Call Details - U.S. participants can dial 877-300-8521, while international participants can call 412-317-6026 to join the conference call [2] - A replay of the conference call will be available on the V2X website for one year and via telephonic replay until August 18, 2025 [3] Company Overview - V2X employs approximately 16,000 professionals and focuses on national security, defense, civilian, and international markets [4] - The company utilizes AI and machine learning to address challenges across various operational domains [4]

Group 1 - iShares A.I. Innovation and Tech Active ETF (NYSEARCA: BAI) presents a compelling investment opportunity for exposure to the technology sector, particularly focusing on artificial intelligence [1] - The investment is characterized as a high-risk, high-reward option, serving as a proxy for the NASDAQ 100 [1] Group 2 - The author has a strong background in finance, holding a Master's in Banking & Finance and extensive experience in corporate finance, M&A, and investment analysis [1] - The focus areas of expertise include real estate, renewable energy, and equity markets, with skills in financial modeling, valuation, and qualitative analysis [1]

Core Insights - The demand for gynecology surgical instruments is increasing due to the rising prevalence of gynecological diseases and government investments in women's health, with a projected market growth rate of 8.26% CAGR from 2024 to 2032 [1] - Hologic's GYN Surgical business has shown a 7.6% CAGR over the past decade, driven by the MyoSure suite and the Fluent fluid management system [1][8] - The launch of the Fluent Pro system in late 2024 is expected to enhance MyoSure's performance and user experience, contributing positively to Hologic's Surgical performance [2] Market Position and Growth - Hologic's International Surgical segment remains the leading revenue driver, supported by investments in market development for minimally invasive GYN products [2] - Legacy NovaSure devices are gaining traction in Europe, despite declining volumes in the U.S., indicating significant expansion opportunities in international markets [3] - Inorganic investments, such as the acquisitions of Acessa Health and Gynesonics, have strengthened Hologic's product offerings and global market reach [4] Competitive Landscape - Hologic faces competition from major companies like Johnson & Johnson and Medtronic in the GYN Surgical space [5] - Johnson & Johnson's MedTech segment reported $8 billion in sales for Q1 2025, with a 4.1% year-over-year growth [6] - Medtronic's Medical Surgical Portfolio saw a 2% increase in Q4 2025, with expectations for improved growth as it expands its robotic platform [6] Financial Performance - Hologic's stock has declined by 8.7% year-to-date, slightly better than the industry's 9.1% decline [7] - The company is trading at a forward 12-month earnings multiple of 14.85, which is lower than the industry average of 28.39 [9] - Consensus estimates for Hologic's fiscal 2025 and 2026 earnings show a bearish trend, with current estimates remaining stable [10][11]

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation, alleging that the company misrepresented the effectiveness of its restructuring plan following a failed merger with Amazon, leading to significant investor losses [3][4]. Group 1: Lawsuit Details - The class action represents investors who purchased iRobot securities between January 29, 2024, and March 11, 2025, with a deadline of September 5, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that iRobot overstated the stability provided by its restructuring plan, raising doubts about its long-term viability as an independent company [3]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share for Q4 and the full year 2024, with revenue of $172 million, marking a 44% decline from the previous year [4]. - The company's statement indicated "substantial doubt" about its ability to continue as a going concern for at least the next 12 months, which led to a stock price drop of over 51% following the announcement [4].

Group 1 - ARK Innovation ETF (ARKK) has reached a 52-week high, increasing approximately 92.4% from its 52-week low of $36.85 per share [1] - The ETF focuses on "disruptive innovation," investing in companies involved in DNA technologies, automation, robotics, energy storage, artificial intelligence, and Fintech [1] - Cathie Wood, CEO of Ark Investment Management, has made significant moves by purchasing shares of CRISPR Therapeutics AG and Beam Therapeutics Inc., while selling shares of 908 Devices Inc. and Roku Inc., indicating a bullish stance on gene-editing technologies [2] Group 2 - ARKK shows a weighted alpha of 60.23 and a 20-day volatility of 29.55%, suggesting potential for continued strength and gains for investors [4] - Despite market turbulence, Cathie Wood maintains a positive outlook on the transformative power of emerging technologies [3]